The availability of a rule-in-rule-out test for Alzheimer’s disease in primary care settings is likely to drive efficiencies throughout the care continuum.

Adaptyx Biosciences announced today it has raised $14 million in seed financing, bringing total funding to $23 million since inception. The round was led by Interlagos, with significant participation ...

Patients with muscle-invasive bladder cancer who test positive for circulating tumor (ct)DNA after surgery to remove the ...

According to the release, this is the first study globally to demonstrate that Sinapic acid, when administered orally, can accelerate diabetic wound healing in preclinical models. The research ...

Adaptyx Biosciences announced today that it raised $14 million in seed funding to support its multi-analyte molecular ...

After arriving in Los Angeles with a dream and determination, Dr. Ramezani turned challenges into a thriving dental practice ...

By combining proteasome inhibitors with Lys05, a drug that impairs autophagy, the team was able to shut down AML’s detour. In ...

The FDA has cleared the Elecsys pTau181 test as an aid in early detection of amyloid pathology in the primary care setting for adults aged 55 years and older presenting with signs, symptoms or ...

Natural products derived from microorganisms are a promising source of new active ingredients, but are often produced only in ...

A blood test that screens for more than 50 cancers is correct in 62% of cases where it thinks people may have the disease, a ...

The FDA has granted 510(k) clearance to a blood-based biomarker test indicated for early detection of Alzheimer’s disease and other causes of cognitive decline within a primary care setting, according ...

Q: I was told I have an elevated level of some protein (troponin) in my blood and that means I had a heart attack. But I ...